SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global plasmid DNA manufacturing market was valued at US$ 65.1million in 2017, and is projected to exhibit a CAGR of 23.7% over the forecast period (2018 – 2026).
Key Trends and Analysis of the Plasmid DNA Manufacturing Market:
Key players in the market are focused on adopting strategies such as mergers and acquisitions to enhance their product portfolio. For instance, in February 2016, Agilis Biotherapeutics, LLC (Agilis) and Waisman Biomanufacturing entered into an exclusive partnership agreement for the production of Agilis’ novel gene therapy product, AGIL-FA, for treatment of Friedreich’s ataxia (FA).
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2593
Europe region is expected to witness significant growth in the plasmid DNA manufacturing market due to adoption of strategies such as collaborations by market players. For instance, in May 2018, PlasmidFactory GmbH & Co. KG collaborated with Sirion-Biotech GmbH, Vibalogics GmbH, and PROGEN, for manufacturing adeno-associated virus (AAV) vector. This collaboration was done in order to create easy workflow from plasmid manufacturing to GMP production, and analytics of recombinant AAV to fulfil the AAV vector demands of customers.
Moreover, an increase in the number of viral vector manufacturing facilities to cater to requirements of GMP grade vectors for clinical trials, is expected to propel the market growth. For instance, in 2018, LakePharma, Inc., as U.S. based Biologics Company, inaugurated a cGMP microBiomanufacturing Center for commercial manufacturing of non-GMP and fully compliant GMP-grade plasmid DNA.
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/plasmid-dna-manufacturing-market-2593
Key Market Takeaways:
- The plasmid DNA manufacturing market is expected to exhibit a CAGR of 23.7% during the forecast period (2018 – 2026), as a result of increasing number of patients opting for gene therapy. For instance, Adeno-associated (AAV2) vectors carrying the therapeutic gene (RPE65) leads to improved vision of individuals suffering from Leber’s Congenital Amaurosis.
- Moreover, according to data published by the Journal of Gene Medicine, March 2018, an estimated 2,600 gene therapy clinical trials were ongoing, completed, or have been approved in 36 countries.
- Key players in the market are focused on research & development, expansion, and collaboration activities in order to enhance their market share. For instance, in January 2019, Sarepta Therapeutics, Inc. and Aldevron announced their collaboration. This collaboration provided Sarepta with Aldevron’s manufacturing slots and capacity for production of GMP grade plasmid for various programs related to gene therapy.
- Key players operating in the global plasmid DNA manufacturing market include Cobra Biologics and Pharmaceutical Services, VGXI, Inc., Aldevron, Kaneka Corporation, Nature Technology Corporation, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, and Waisman Biomanufacturing.
Buy this report now @ https://www.coherentmarketinsights.com/insight/buy-now/2593
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
